3% of battlefield deaths are due to uncontrolled bleeding from the limbs.
50% of all the injured in the battlefield sustain major injuries in the limbs. In addition, when user is under stress, today’s manual tourniquet applications have only 67% success when user is under stress. 

Product & Technology:

Xmetix’s product is smart clothing designed to save lives on the battlefield. Xmetix smart pants and shirt are capable of identifying and responding to limb's bleeding injury autonomously. Xmetix's technology includes both the injury detection and bleeding control features integrated into the clothing:
A. Sensor mesh technology: printed on the fabric without changing its specifications or compromising comfort.
B. Adaptive onboard software: algorithms tuned to detect and classify user status and the need to activate the automated bleeding control.
C. Self-powered tourniquets: miniature electromechanical elements designed to stop hand or leg bleeding within seconds range based on radial pressure.

Go to market strategy:

Focus on military and police customers. Establishment of partnerships with US OEM. Initial focus will be on special forces as they are identified as potential early adopters for the product.

IP & Regulation:

The company’s technology is protected by a patent covering both the proprietary detection process and the reactive portion of the system.
The company is aiming to achieve product classification of its product as a de-novo medical device in the USA and Europe.


Xmetix’s main competitor is the manual tourniquet. The gold standard tourniquet is the Combat Application Tourniquet (CAT). 


Irad Kuhnreich: Founder and CEO, retired IDF Major Former founder and CEO of Airbase Systems Ltd., a sensor networks startup purchased by Perkin Elmer corporation. Served as R&D engineer in RAFAEL weapon systems and.

Eviatar Kuhnreich: Founder and Medical lead, MD, General surgeon at Bnei Zion medical center, reserves lieutenant in the IDF (combat medicine). Former Israeli naval commando team member (SEAL).

German Shillov: Data Scientist , Former Shutterfly inc. OS developer, Served as software developer in RAFAEL weapon systems.

Zohar Gendler: Director,  Managing Partner & CEO of NGT3VC. Former CEO & director of Beta-O2 Technologies (developed proprietary implantable bio-artificial pancreas). Served as CEO of the Technion Technological Incubator for 11 years. Led the establishment and investment in 53 companies, such as Prolor Biotech (sold to OPKO, $480M), Mazor Robotics (Sold to Medtronic, $1.6B), ReWalk (NASDAQ: RWLK), Corindus (Sold to Siemens, $1.1B), and many others.

Current Status:

Xmetix has developed a prototype suitable for field trials and is currently conducting these trials, demonstrating with live gunshots the ability to detect and classify penetrating trauma based on its printed sensor mesh.

Contact Us : 

 Irad Kuhnreich- CEO 

Mobile :  +972-52-3934031  

Fax :       +972-4-6098611

E-mail : irad@xmetix.com


Investors - Contact Us

Entrepreneurs - Contact Us